Prime Medicine ($PRME) Stock Forecast: Up 5.2% Today

What is Prime Medicine?

Prime Medicine (NYSE: PRME) is a biotech company specializing in gene editing technologies. The stock rose 4.8% to $4.02 today.

Why is Prime Medicine going up?

PRME stock is up 5.2% on Feb 26, 2026 16:36

• Unusual options trading activity with a significant increase in call options indicates a bullish sentiment among traders.
• The company's "Moderate Buy" consensus from analysts and substantial institutional investor stake add to the positive market momentum.
• Participation in upcoming investor conferences to discuss its Prime Editing platform and therapeutic programs likely boosted investor confidence, contributing to the stock's upward trend.

PRME Price Chart

PRME Technical Analysis

PRME News

Stock Traders Buy Large Volume of Call Options on Prime Medicine (NYSE:PRME)

Prime Medicine (NYSE:PRME) experienced unusual options trading activity on Wednesday, with traders buying 3,638 call options, a 79% increase over typical daily volume, signaling bullish sentiment. Following this, PRME shares rose 4.8% to $4.02. Analysts maintain a "Moderate Buy" consensus with an average price target of $7.21, and institutional investors hold a significant 70.37% stake in the company.

https://www.marketbeat.com/instant-alerts/stock-traders-buy-large-volume-of-call-options-on-prime-medicine-nyseprme-2026-02-25/

Prime Medicine to Participate in Upcoming Investor Conferences

Prime Medicine, Inc. announced its participation in three upcoming investor conferences in March 2026, including the TD Cowen 46th Annual Health Care Conference, the Jefferies Biotech on the Beach Summit, and The Citizens Life Sciences Conference. The company will host fireside chats and 1x1 meetings to discuss its proprietary Prime Editing platform and its diversified portfolio of investigational therapeutic programs. Live audio webcasts of the fireside chats will be available on the company's website.

https://www.globenewswire.com/news-release/2026/02/25/3244524/0/en/prime-medicine-to-participate-in-upcoming-investor-conferences.html

Trending Today

Ethereum ($ETH) Crypto Forecast: Up 5.2% Today

Bitcoin ($BTC) Crypto Forecast: Down 5.9% Today

Binance Coin ($BNB) Crypto Forecast: Down 5.0% Today

Prime Medicine Price History

06.00.2026 - PRME Stock was up 7.6%

• PRME observed a rise in its stock price after receiving a favorable assessment from an investment firm, which set an Outperform rating and a $6 price target. The company's innovative gene editing treatments for liver and lung diseases were highlighted as particularly noteworthy.
• The release of successful Phase 1/2 clinical trial results for PM359 further solidified investor belief in PRME. These results were published, showcasing the effectiveness and safety of Prime Editing technology for chronic granulomatous diseases in a well-known medical journal.
• The positive outcomes from the clinical studies, such as swift neutrophil engraftment and lasting patient improvements, likely influenced the favorable market reception towards PRME.
• In essence, the combination of encouraging analyst feedback, groundbreaking clinical trial data, and the potential of Prime Medicine's gene editing technology were key factors behind the surge in PRME stock value today.

24.01.2026 - PRME Stock was up 11.4%

• Jacob Funds' investment in Prime Medicine reflects growing confidence in the company's potential to revolutionize the treatment of various diseases through its precise gene editing capabilities.
• The positive results from Prime Medicine's first clinical trial are likely driving investor optimism and contributing to the bullish movement in PRME stock.
• The market's reaction suggests that investors see Prime Medicine as a promising player in the gene therapy space, with the potential for significant growth and impact in the healthcare industry.

04.01.2026 - PRME Stock was down 5.7%

• Despite a substantial US$110 million decrease in market cap for Prime Medicine, Inc. (PRME) last week, institutional investors show confidence in the company's strong long-term returns.
• Strong one-year gains of 44% potentially offset the recent market cap decline, displaying resilience amidst short-term market fluctuations.
• Institutional ownership stands at 44%, with significant insider holdings indicating optimism about the company's future, potentially explaining the lack of concern among investors regarding the recent market downturn.
• The stock price appears sensitive to institutional trading activities, underscoring the influence of their decisions on market movements and emphasizing the need to monitor institutional sentiment for insights into PRME's future performance.

10.01.2026 - PRME Stock was down 5.1%

• Despite receiving a "Moderate Buy" consensus rating from seven brokerages, PRME's stock saw a significant decline.
• The average 12-month price target of $7.21 indicates optimism in the company's future performance, but the market reacted negatively.
• Institutional investors holding a substantial portion of the stock may have contributed to the heightened selling pressure, leading to the bearish movement.
• The disconnect between the positive analyst recommendations and the actual market performance suggests that external factors or unexpected news may have influenced the stock's decline.

22.00.2026 - PRME Stock was up 7.0%

• A significant increase in stake by Sumitomo Mitsui Trust Group Inc. by 127.7% in the third quarter reflects strong confidence in PRME's future prospects.
• The high institutional ownership of about 70.37% suggests strong support from large investors, potentially benefiting the stock price.
• Analysts' "Moderate Buy" rating and the average price target of $7.21 may have contributed to the positive sentiment, signaling promising growth potential for PRME.

14.00.2026 - PRME Stock was up 5.1%

• PRME stock experienced a bullish movement today following the company's announcement of an updated corporate strategy for its Prime Editing platform, which included detailed timelines for clinical and regulatory milestones in liver, lung, and oncology programs.
• The positive market response can be attributed to Prime Medicine's progress in advancing its gene-editing technology, with plans to file regulatory applications and initiate Phase 1 trials for liver-focused candidates in 2026, as well as the anticipation of significant milestones from a partnership.
• Investors likely reacted favorably to the company's projected expansion of its pipeline through organic growth and partnerships, showcasing the broad therapeutic potential of Prime Medicine's platform in addressing a wide range of genetic diseases.
• Overall, the bullish movement in PRME stock reflects investor confidence in the company's innovative approach to gene editing and the promising developments in its Prime Editing technology, positioning Prime Medicine as a key player in the biotech industry.

15.00.2026 - PRME Stock was down 6.4%

• Recently, Prime Medicine (PRME) witnessed a significant decline in its stock value, influenced by several factors:
• The company disclosed a quarterly EPS loss that exceeded expectations, coupled with lower revenue figures, indicating unfavorable profit margins, which potentially raised concerns among stakeholders regarding its financial standing.
• Analyst assessments were mixed, with several issuing "sell" recommendations, potentially contributing to the stock's downward trajectory.
• Despite unveiling an updated corporate strategy for its Prime Editing platform and sharing detailed timelines for its clinical and regulatory initiatives, market response suggests a sense of investor skepticism regarding the company's capacity to meet its targets.
• The projected submission of regulatory applications and commencement of Phase 1 trials for liver-focused candidates in 2026 may not have been adequate to counterbalance the negative market sentiment stemming from Prime Medicine's recent financial outcomes.

27.00.2026 - PRME Stock was up 5.1%

• An analyst reaffirmed a "buy" rating for Prime Medicine (PRME.US) and kept a target price of $5.
• The positive analyst rating likely played a role in the stock's upward movement.
• Investor optimism about Prime Medicine's gene editing therapies and the analyst's target price could have influenced the stock's performance.
• The news of the analyst's rating may have increased investor confidence in the company's future, leading to heightened buying activity and an increase in the stock price.

26.01.2026 - PRME Stock was up 5.2%

• Unusual options trading activity with a significant increase in call options indicates a bullish sentiment among traders.
• The company's "Moderate Buy" consensus from analysts and substantial institutional investor stake add to the positive market momentum.
• Participation in upcoming investor conferences to discuss its Prime Editing platform and therapeutic programs likely boosted investor confidence, contributing to the stock's upward trend.

24.11.2025 - PRME Stock was down 5.0%

• Despite falling short of projected quarterly EPS and showing minimal revenue, an upgrade to a "strong-buy" rating by Lifesci Capital could have led to initial investor optimism.
• Nevertheless, the company's notable negative margins and return on equity, combined with other entities issuing "sell" recommendations, may have fueled increased selling activity and the downward movement in the stock price.
• Speculation arose among investors due to the CEO hinting at a shift in focus towards larger opportunities in different diseases, potentially contributing to the uncertainty surrounding the stock and its decline.
• The fluctuating opinions of analysts, the company's strategic adjustments, and its financial performance likely played a crucial role in the bearish trend witnessed in PRME's market performance for the day.

03.01.2026 - PRME Stock was down 8.7%

• Despite Prime Medicine, Inc. experiencing a US$110 million decrease in market cap last week, institutional investors have still benefited from 36% gains over the past year.
• The high sensitivity of the stock price to institutional trading actions, with institutions holding a substantial 44% ownership in the company, likely contributed to the bearish movement.
• The concentration of ownership among the top 8 shareholders, who collectively own more than half of the company's shares, could have influenced the market sentiment and led to the downward trend in PRME stock.
• The long-term gains for institutional investors juxtaposed with the recent market cap decrease may indicate a temporary setback rather than a fundamental issue with the company, potentially offering a buying opportunity for savvy investors looking at the bigger picture.

08.00.2026 - PRME Stock was down 5.7%

• The bearish movement in PRME stock could be due to investors having high expectations from the upcoming presentation at the J.P. Morgan Healthcare Conference, leading to profit-taking or a "sell the news" reaction.
• There might have been concerns raised during the presentation about the timeline for bringing their gene editing technology to market, causing uncertainty among investors.
• It's possible that some investors were expecting more concrete updates on the progress of their Prime Editing platform or the results of ongoing clinical trials, leading to disappointment and a sell-off in the stock.